Larvol Delta - Equillium-Reports-on-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-and-Clinical-Highlights

Alzumab (itolizumab) - Biocon, Equillium, Ono Pharma

EQ101 - Equillium

https://www.businesswire.com/news/home/20240325649617/en/Equillium-Reports-on-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-and-Clinical-Highlights

Mar 25, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next